Medicare Enrolled
Dr. Glenn Wong, DO
Hematology & Oncology · Santa Cruz, CA
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Wong from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Wong?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Wong
Dr. Glenn Wong is a hematology & oncology specialist in Santa Cruz, CA, with 19 years of NPI registration. Based on federal Medicare data, Dr. Wong performed 103,970 Medicare services across 2,312 unique beneficiaries.
Between the years covered by Open Payments, Dr. Wong received a total of $806 from 22 pharmaceutical and/or device companies across 33 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Wong is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice
▲ Top 7% volume in CA
$806 industry payments
Medicare Practice Summary
Medicare Utilization ↗103,970
Medicare services
Top 7% in CA for hematology & oncology
2,312
Unique beneficiaries
$18
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~5,472 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Nivolumab injection (Opdivo) | 20,320 | $24 | $65 |
| Filgrastim injection (Zarxio) for white blood cells An injection of the biosimilar medication filgrastim-sndz (Zarxio) with a dosage of 1 microgram. |
16,200 | $0 | $1 |
| Pembrolizumab injection (Keytruda) | 8,400 | $43 | $88 |
| Iron infusion (Feraheme) An injection of ferumoxytol used to treat iron deficiency anemia in patients not on dialysis. |
8,160 | $0 | $2 |
| Anti-nausea injection (fosaprepitant) An injection of fosaprepitant, a medication used to prevent nausea and vomiting. |
7,350 | $0 | $3 |
| Denosumab injection (Prolia/Xgeva) | 6,660 | $19 | $45 |
| Daratumumab injection (Darzalex) An injection containing daratumumab and hyaluronidase-fihj administered under the skin. |
6,480 | $38 | $83 |
| Golimumab infusion (Simponi Aria) Administration of golimumab medication directly into a vein. This code specifies the dosage amount of 1 milligram for intravenous delivery. |
5,700 | $10 | $75 |
| Paclitaxel chemotherapy injection | 3,285 | $0 | $1 |
| Rituximab-pvvr biosimilar injection, 10 mg An injection of rituximab-pvvr, a biosimilar medication, administered in a 10 mg dose. |
2,620 | $21 | $190 |
| BCG treatment for bladder cancer | 2,600 | $2 | $8 |
| Epoetin alfa injection (Retacrit) for anemia An injection of a biosimilar form of epoetin alfa used for non-end-stage renal disease purposes. The dose administered is 1000 units. |
2,182 | $6 | $18 |
| Abatacept infusion (Orencia) An injection of abatacept administered under the direct supervision of a physician. This code is used for Medicare when the drug is not self-administered. |
2,125 | $34 | $104 |
| Epoetin alfa injection (Procrit) for anemia An injection of epoetin alfa containing 1000 units for use in patients not on end-stage renal disease (ESRD) dialysis. |
2,080 | $6 | $33 |
| Anti-nausea injection (ondansetron/Zofran) | 1,700 | $0 | $1 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
1,119 | $0 | $1 |
| Infliximab-abda biosimilar injection, 10 mg This code represents the administration of a 10 mg dose of infliximab-abda, a biosimilar medication. It covers the injection of this specific pharmaceutical product. |
1,100 | $29 | $117 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
794 | $100 | $364 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
653 | $151 | $489 |
| Zoledronic acid injection, 1 mg An injection of zoledronic acid administered at a dose of 1 mg. |
521 | $7 | $202 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
465 | $60 | $356 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
381 | $125 | $716 |
| Cyclophosphamide, 100 mg | 357 | $15 | $145 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
312 | $13 | $107 |
| Additional hour of intravenous infusion This code represents each additional hour of intravenous infusion beyond the initial hour for therapy, prevention, or diagnosis. |
275 | $19 | $106 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
269 | $14 | $110 |
| Pegfilgrastim injection, 0.5 mg An injection of pegfilgrastim, a medication that stimulates the production of white blood cells. This specific code applies to the brand-name drug and excludes biosimilar versions. |
228 | $63 | $907 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
129 | $26 | $154 |
| Non-hormonal chemotherapy injection This procedure involves administering non-hormonal anti-neoplastic chemotherapy medication via injection into the skin or muscle tissue. |
123 | $70 | $318 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
120 | $27 | $156 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
117 | $61 | $360 |
| Blood sample collection from implanted device This procedure involves drawing a blood sample directly from a medical device that has been surgically placed in the body. |
102 | $25 | $118 |
| Carboplatin chemotherapy injection, 50 mg Administration of a 50 mg dose of carboplatin, a chemotherapy medication, via injection. |
100 | $2 | $17 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
93 | $1 | $2 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 93 | $133 | $792 |
| Office visit for established patient An office visit for an existing patient that may not require the healthcare professional to be present. |
72 | $21 | $74 |
| Normal saline infusion, 1000 cc Administration of 1000 cc of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater solution. |
72 | $2 | $15 |
| New patient office visit, complex (60-74 min) | 67 | $185 | $697 |
| Intravenous drug injection A procedure involving the administration of a medication or substance directly into a vein. |
64 | $34 | $281 |
| Bladder instillation of anti-cancer drug A procedure where an anti-cancer medication is introduced directly into the bladder. This method delivers the treatment locally to the bladder tissue. |
57 | $73 | $567 |
| Intravenous hydration infusion, 31-60 minutes Administration of fluids into a vein to maintain hydration. This procedure involves an infusion lasting between 31 and 60 minutes. |
57 | $31 | $291 |
| Subcutaneous or intramuscular chemotherapy injection This procedure involves administering anti-cancer hormonal medication through an injection into the tissue under the skin or into a muscle. |
52 | $32 | $164 |
| Concurrent intravenous infusion Administration of medication or fluid into a vein for therapy, prevention, or diagnosis while another infusion is being given. |
50 | $18 | $98 |
| Intravenous push injection of new drug or substance A healthcare provider injects a new medication or substance directly into a vein using a push technique. |
45 | $53 | $309 |
| Methylprednisolone injection, up to 125 mg An injection of methylprednisolone sodium succinate, a corticosteroid medication, with a dosage of up to 125 mg. |
45 | $4 | $16 |
| Venipuncture for blood collection A procedure to draw blood from a vein for medical testing or analysis. |
41 | $87 | $298 |
| Additional hour of intravenous hydration This code represents each additional hour of intravenous fluid administration beyond the initial hour. It is used to bill for extended hydration therapy. |
36 | $12 | $74 |
| Normal saline infusion, 500 ml Administration of sterile normal saline solution through an intravenous line. This procedure involves the infusion of a 500 ml unit of the solution. |
32 | $1 | $8 |
| Prolonged office E/M service, first 15 minutes This code is used for additional time spent by a physician beyond the maximum required time of a primary office or outpatient evaluation and management service. It is billed in 15-minute increments based on total time spent on the date of the primary service. |
27 | $28 | $130 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
20 | $131 | $554 |
| Unclassified drug A medication that does not fit into standard HCPCS or CPT classification categories. |
20 | $0 | $7 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
16.9% high complexity
78.4% medium
4.8% routine
Industry Payment Transparency
Open Payments through 2024 ↗$806
Total received (2018-2024)
Avg $115/year across 7 years
Bottom 31% in CA for hematology & oncology
22
Companies
33
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$681 (84.6%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$124 (15.4%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$498
2023
$45
2022
$38
2021
$24
2020
$13
2019
$17
2018
$171
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Celgene Corporation
$67
Novartis Pharmaceuticals Corporation
$47
E.R. Squibb & Sons, L.L.C.
$42
ARRAY BIOPHARMA INC
$42
Amgen Inc.
$40
GlaxoSmithKline, LLC.
$33
Eisai Inc.
$32
Merck Sharp & Dohme LLC
$32
PUMA BIOTECHNOLOGY, INC.
$29
Astellas Pharma US Inc
$28
PFIZER INC.
$24
Daiichi Sankyo Inc.
$24
Incyte Corporation
$22
Genmab U.S., Inc.
$22
Janssen Biotech, Inc.
$15
Top 3 companies account for 31.4% of 2024 payments
All-time payments by company (2018-2024) ›
Alexion Pharmaceuticals, Inc.
$114
Celgene Corporation
$67
Acrotech Biopharma LLC
$62
Novartis Pharmaceuticals Corporation
$47
PFIZER INC.
$44
E.R. Squibb & Sons, L.L.C.
$42
ARRAY BIOPHARMA INC
$42
Janssen Biotech, Inc.
$41
Amgen Inc.
$40
GlaxoSmithKline, LLC.
$33
Eisai Inc.
$32
Merck Sharp & Dohme LLC
$32
PUMA BIOTECHNOLOGY, INC.
$29
Astellas Pharma US Inc
$28
Foundation Medicine, Inc.
$24
Daiichi Sankyo Inc.
$24
Incyte Corporation
$22
Genmab U.S., Inc.
$22
EMD Serono, Inc.
$18
Stemline Therapeutics Inc.
$17
Merck Sharp & Dohme Corporation
$13
Seattle Genetics, Inc.
$12
Top 3 companies account for 30.2% of all-time payments
Associated products mentioned in payments ›
ADCETRIS · BAVENCIO · BELEODAQ · BRAFTOVI · ELZONRIS · ERLEADA · EVENITY · Enhertu · Epkinly · FOUNDATIONONE · INLYTA · JAKAFI · JEMPERLI · KEYTRUDA · KISQALI · LENVIMA · LUTATHERA · Lenvima · MYLOTARG · OPDIVO · Padcev · REBLOZYL · SOLIRIS · XALKORI
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (85%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Hematology & oncology specialists within 10 mi
39
Per 100K population
14.7
County median income
$109,266
Nearest hospital
DOMINICAN HOSPITAL
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Wong is a mixed practice specialist, with above-average Medicare volume (top 7% in CA), with low-engagement industry engagement, with 19 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Wong experienced with nivolumab injection (opdivo)?
Based on Medicare claims data, Dr. Wong performed 20,320 nivolumab injection (opdivo) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Wong receive payments from pharmaceutical companies?
Yes. Dr. Wong received a total of $806 from 22 companies across 33 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Wong's costs compare to other hematology & oncology specialists in Santa Cruz?
Dr. Wong's average Medicare payment per service is $18. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Wong) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncology Specialists in Santa Cruz
Browse hematology & oncology specialists in Santa Cruz ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in CA
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in CA
Which CA hematology & oncology specialists receive the most from drug and device companies.
By company
Alexion Pharmaceuticals, Inc. Payments to Doctors
See all physicians who received payments from Alexion Pharmaceuticals, Inc.
By company
Celgene Corporation Payments to Doctors
See all physicians who received payments from Celgene Corporation.
By company
Acrotech Biopharma LLC Payments to Doctors
See all physicians who received payments from Acrotech Biopharma LLC.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology